izpis_h1_title_alt

Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia
Obradović, Marko (Avtor), Mrhar, Aleš (Avtor), Kos, Mitja (Avtor)

URLURL - Predstavitvena datoteka, za dostop obiščite http://eurpub.oxfordjournals.org/cgi/search?pubdate_year=2010&volume=&firstpage=&DOI=&author1=kos&author2=&title=&andorexacttitle=and&titleabstract=&andorexacttitleabs=and&fulltext=&andorexactfulltext=and&fmonth=Jan&fyear=1991&tmonth=Aug&tyear=2010&fdatedef=1+January+1991&tdatedef=1+August+2010&flag=&RESULTFORMAT=1&hits=10&hitsbrief=25&sortspec=relevance&sortspecbrief=relevance&sendit=Search Novo okno

Izvleček
Background: The objective of the present study is to evaluate the cost-effectiveness of human papillomavirus (HPV) vaccination alongside cervical cancer screening programme in Slovenia. Methods: A previously published Markov model representing natural history of HPV infection was adapted to Slovenian context. The model followed a cohort of 12-year-old girls to 85-year-old women. Two strategies were compared: HPV vaccination alongside conventional cytological screening versus screening alone. Analysis was performed from the health care payer perspective. Results: Vaccination with screening compared with screening alone was associated with an incremental cost-effectiveness ratio (ICER) of 23 178 EUR per quality adjustedlife-year (QALY) gained and 54 536 EUR per life-year gained (LYG) at the discounting rate of 5%. Sensitivity analyses demonstrated that the ICER was most sensitive to the need for booster dose and to different values of discount rates. In case the booster dose was assumed 10 years after initial vaccination, the ICER value was increased to 58 690 EUR per QALY. On the otherhand, using lower values of discount rates than the base case 5% significantly reduced the ICER value. Conclusion: According to the cost-effectiveness thresholds of 30 000 EUR per QALY which was adopted by the Health Council in Slovenia, HPV vaccination alongside screening programme can be regarded as cost-effective. However, cost-effectiveness of HPV vaccination would become questionable in case a booster dose was needed to provide lifetime protection.

Jezik:Angleški jezik
Ključne besede:stroški zdravljenja, rak materničnega vratu, citološke raziskave, HPV
Vrsta gradiva:Delo ni kategorizirano (r6)
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:FFA - Fakulteta za farmacijo
Leto izida:2010
Št. strani:str. 415-421
Številčenje:vol. 20, no. 4
UDK:615.2
ISSN pri članku:1101-1262
COBISS.SI-ID:2834033 Povezava se odpre v novem oknu
Število ogledov:1073
Število prenosov:163
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
 
Skupna ocena:(0 glasov)
Vaša ocena:Ocenjevanje je dovoljeno samo prijavljenim uporabnikom.
:
Objavi na: Bookmark and Share

Gradivo je del revije

Naslov:European journal of public health
Skrajšan naslov:Eur. j. public health
Založnik:Almqvist & Wiksell International
ISSN:1101-1262
COBISS.SI-ID:14341593 Novo okno

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Komentarji

Dodaj komentar

Za komentiranje se morate prijaviti.

Komentarji (0)
0 - 0 / 0
 
Ni komentarjev!

Nazaj